Regeneus’ osteoarthritis cell therapy to launch in Singapore
THE ROADHOUSE PHARMACY: Regeneus Ltd (ASX: RGS) has announced plans to open the HiQCell Regenerative Medicine Clinic in Singapore.
The company also announced the appointment of specialist sports physician, Dr Patrick Goh, as medical director.
Regenus said, through the clinic, Dr Goh will provide patients in Singapore with access to the company’s HiQCell, a cell therapy for the treatment of osteoarthritis, with first treatments expected to commence in late 2014.
As well as assuming the role of medical director at the HiQCell Regenerative Medicine Clinic, Dr
Goh will become the initial treating medical practitioner for the HiQCell procedure.
“HiQCell provides a viable treatment option for mid-stage, age or impact related osteoarthritis patients who might otherwise face ongoing debilitating pain, loss of function, inability to play sport and reduced quality of life,” Dr Goh said in Regenus’ announcement to the Australian Securities Exchange.
“I am very pleased to be able to offer this treatment to my patients.”
The HiQCell Regenerative Medicine Clinic will be located at the Camden Medical Centre in
Singapore’s premier medical services district on Orchard Road where a new state of the art cell-processing laboratory has been established.
Regenus said Singapore provides a natural first overseas market for its HiQCell therapy saying the country is recognised as a leading edge medical services hub for both local and international patient treatments.
Regenus explained the HiQCell treatment involves harvesting a small amount of a patient’s own stem cells from their adipose (fat) tissue and after separating and concentrating the regenerative cells these are re-injected in osteoarthritic-affected joints such as knees, hips and ankles.
The company claims the HiQCell treatment aims to reduce inflammation and repair damaged tissue is carried out under the supervision of the treating medical practitioner.
HiQCell has been used to treat more than 500 patients and over 1,000 arthritic joints.
The cell therapy procedure is supported by safety data from a randomised controlled clinical trial and long-term safety and efficacy data is tracked through Australia’s first Joint Registry for stem cell therapy.
Website: www.regeneus.com.au
www.hiqcell.com.au